ResultsIQ

ResultsIQ › Latest results › Wanbury Limited

Wanbury Limited Q2 FY26 results press release summary

NSE: WANBURY · BSE: 524212

Results press release of 18 Nov 2025, summarised by AI from the filing.

Turned EBITDA positive, supported by launch of C-red-advanced liposomal iron supplement and improved field productivity.

Key takeaways

  1. Formulations Turned EBITDA positive, supported by launch of C-red-advanced liposomal iron supplement and improved field productivity.
  2. Risks General economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments could cause actual results to differ.

Original filing on BSE

Wanbury Limited Q1 FY27 results

As filed: Revenue ₹166 cr (+2% year on year), EBITDA ₹16.2 cr (−38% year on year), PAT ₹3.2 cr (−75% year on year), EBITDA margin 9.8% (−614 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹165 cr (−4% year on year), EBITDA ₹29.9 cr (+3% year on year), PAT ₹21.7 cr (−1% year on year), EBITDA margin 18.1% (+128 bps). Score 29 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin rose 128 bps year on year. Tax rate -43%. Share price after the results: −11.1% in 27 days (Nifty 500: +2.0%).
  • Q3 FY26: Revenue ₹162 cr (+22% year on year), EBITDA ₹26.7 cr (+105% year on year), PAT ₹15.8 cr (+300% year on year), EBITDA margin 16.4% (+666 bps). Score 69 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 666 bps year on year. Tax rate 1%. Share price after the results: −3.5% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹160 cr (−1% year on year), EBITDA ₹26.0 cr (+37% year on year), PAT ₹15.0 cr (+88% year on year), EBITDA margin 16.3% (+445 bps). Score 60 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 445 bps year on year. Tax rate 0%. Profit rose ₹7.0 cr on a year ago, more than the ₹1.0 cr it added the year before. Share price after the results: −4.7% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹163 cr (+24% year on year), EBITDA ₹26.0 cr (+136% year on year), PAT ₹13.0 cr (+300% year on year), EBITDA margin 16.0% (+755 bps). Score 73 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 755 bps year on year. Tax rate 0%. Revenue fell 5% from last quarter. Share price after the results: +2.8% in 30 days (Nifty 500: 0.0%).
  • Q4 FY25: Revenue ₹172 cr (+24% year on year), EBITDA ₹29.0 cr (+71% year on year), PAT ₹20.0 cr (−41% year on year), EBITDA margin 16.9% (+463 bps). Score 71 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 463 bps year on year. Tax rate -5%. Consolidated profit -41% but standalone +150%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +12.5% in 29 days (Nifty 500: +0.5%).
  • Q3 FY25: Revenue ₹133 cr (−9% year on year), EBITDA ₹13.0 cr (−35% year on year), PAT ₹1.0 cr (−90% year on year), EBITDA margin 9.8% (−392 bps). Score 8 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend. EBITDA margin fell 392 bps year on year. Other income 100% of PBT. Tax rate 0%. Revenue fell 17% from last quarter.
  • Q2 FY25: Revenue ₹161 cr (+12% year on year), EBITDA ₹19.0 cr (+12% year on year), PAT ₹8.0 cr (+14% year on year), EBITDA margin 11.8% (0 bps). Score 41 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it. EBITDA margin was flat year on year. Tax rate 0%.

Past price moves after results do not indicate future moves. Not a recommendation.

Wanbury Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.